Abstract
Siah1a has been implicated in numerous signaling pathways because of its ability to induce ubiquitin-mediated degradation of many protein substrates. Siah1a knockout mice are growth-retarded, exhibit early lethality, and display spermatogenic defects. In this study we identified a striking low bone volume phenotype in these mice (trabecular bone volume was halved compared with wild type mice), linking Siah1a to bone metabolism for the first time. Markers of bone formation, including osteoblast numbers and osteoid volume, were decreased by up to 40%, whereas the number of osteoclasts was more than doubled in Siah1a mutant mice. However, ex vivo osteoclast formation occurs normally and hematopoietic osteoclast progenitor cell types were present in normal numbers in Siah1a mutant mice. Moreover, adoptive transfer of Siah1a mutant bone marrow into wild type mice failed to reproduce the osteopenia or increased osteoclast numbers observed in mutant mice. Although ex vivo osteoblast colony formation was normal in Siah1a mutant mice, mineralization from these cells was elevated in cultures from Siah1a mutant mice, which may explain the reduction in osteoid volume seen in vivo. These findings suggest that although Siah1a is clearly essential for normal bone metabolism, the bone defect in Siah1a mutant mice is not due to cell-autonomous requirements for Siah1a in osteoblast or osteoclast formation. We propose that bone metabolism defects in Siah1a mutant mice are secondary to an alteration in an unidentified systemic, paracrine, or metabolic factor in these mice.
Highlights
Ubiquitination is increasingly recognized as an important regulatory mechanism in diverse cellular processes
Osteopenia in Siah1a Mutant Mice—While flushing bone marrow samples from femurs, we noticed that bones from Siah1a mutant mice appeared weaker than those from wild type mice
Consistent with reduced size, we found that spleen, thymus, lymph nodes, and bone marrow from Siah1a knockout mice contained only 30 –50% of the number of white blood cells found in organs from wild type littermates (Table I)
Summary
Antibodies—Unless otherwise stated, antibodies were from BD Pharmingen. The following anti-mouse antibodies were used in this study: anti-B220 (RA3-6B2), anti-CD3 (145-2C11), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-CD28 (37.51), anti-CD40 (3/23), anti-CD45.2 [104], anti-F4/80 (Caltag), anti-Gr-1 (RB6 – 8C5), anti-IgM (FabЈ) fragments (ICN), and anti-Mac-1 (M1/70). For agar colony-forming assays, 5 ϫ 104 white blood cells were cultured in 0.3% agar in Dulbecco’s modified Eagle’s medium supplemented with 20% fetal calf serum and either recombinant human G-CSF (1000 units/ml, Amgen), recombinant murine GM-CSF (1000 units/ml, Peprotech), recombinant murine M-CSF (20 ng/ml, Peprotech), recombinant murine IL-3 (1000 units/ml, Peprotech) or SCF Bone marrow was obtained by flushing femurs with a 23-guage needle and culturing whole bone marrow preparations for 28 days at a starting density of 2 ϫ 106 cells/well in a 24-well plate. After 5– 6 days, primary osteoblasts were harvested and seeded at 104 cells/well in 24-well plates and grown under the same conditions as marrow mineralization cultures (described above). Bones were harvested 8 weeks after injection, and flow cytometry analysis of bone marrow using anti-Mac-1 and antiCD45.2 antibodies demonstrated that more than 99% of myeloid cells were derived from injected marrow
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.